Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis

a case report

Takuya Tsujino, Kiyoshi Takahara, Tomohisa Matsunaga, Yuki Yoshikawa, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Hajime Hirano, Hayahito Nomi, Naokazu Ibuki, Teruo Inamoto, Haruhito Azuma

Research output: Contribution to journalArticle

Abstract

Background: No standard chemotherapy regimen for advanced urothelial cancer has been established, except for cisplatin-based regimens. We report the case of a patient with double primary cancer, urothelial carcinoma of the upper urinary tract and colorectal cancer, who underwent oxaliplatin-based chemotherapies. Case presentation: A 56-year-old Japanese man presented to our hospital with the diagnosis of a left renal pelvic tumor and rectal cancer. Several examinations including ureteroscopic biopsy and computed tomography-guided biopsy were performed; however, the diagnosis of renal pelvic cancer could not be made. Because the rectal cancer had been growing during the course of examination, he underwent five cycles of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan. The volumes of both the rectal cancer and renal pelvic tumor drastically decreased. He then underwent pelvic evisceration with colostomy and ureterocutaneostomy. The histological diagnosis of the renal pelvic tumor was urothelial carcinoma. He is free of disease at 12 months after the treatment. Conclusions: To the best of our knowledge, this is the first report describing a remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy for renal pelvic cancer. We suggest fluorouracil, leucovorin, oxaliplatin, and irinotecan is an effective therapy for patients with advanced urothelial cancer.

Original languageEnglish
Article number99
JournalJournal of Medical Case Reports
Volume11
Issue number1
DOIs
Publication statusPublished - 10-04-2017
Externally publishedYes

Fingerprint

irinotecan
oxaliplatin
Pelvic Neoplasms
Kidney Pelvis
Leucovorin
Fluorouracil
Kidney Neoplasms
Rectal Neoplasms
Neoplasms
Drug Therapy
Therapeutics
Urologic Neoplasms
Carcinoma
Kidney
Biopsy
Colostomy
Cisplatin
Colorectal Neoplasms
Tomography

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Tsujino, Takuya ; Takahara, Kiyoshi ; Matsunaga, Tomohisa ; Yoshikawa, Yuki ; Takai, Tomoaki ; Uchimoto, Taizo ; Saito, Kenkichi ; Tanda, Naoki ; Hirano, Hajime ; Nomi, Hayahito ; Ibuki, Naokazu ; Inamoto, Teruo ; Azuma, Haruhito. / Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis : a case report. In: Journal of Medical Case Reports. 2017 ; Vol. 11, No. 1.
@article{8fe987294a7f4ee3b0388169aa7bb6e8,
title = "Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report",
abstract = "Background: No standard chemotherapy regimen for advanced urothelial cancer has been established, except for cisplatin-based regimens. We report the case of a patient with double primary cancer, urothelial carcinoma of the upper urinary tract and colorectal cancer, who underwent oxaliplatin-based chemotherapies. Case presentation: A 56-year-old Japanese man presented to our hospital with the diagnosis of a left renal pelvic tumor and rectal cancer. Several examinations including ureteroscopic biopsy and computed tomography-guided biopsy were performed; however, the diagnosis of renal pelvic cancer could not be made. Because the rectal cancer had been growing during the course of examination, he underwent five cycles of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan. The volumes of both the rectal cancer and renal pelvic tumor drastically decreased. He then underwent pelvic evisceration with colostomy and ureterocutaneostomy. The histological diagnosis of the renal pelvic tumor was urothelial carcinoma. He is free of disease at 12 months after the treatment. Conclusions: To the best of our knowledge, this is the first report describing a remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy for renal pelvic cancer. We suggest fluorouracil, leucovorin, oxaliplatin, and irinotecan is an effective therapy for patients with advanced urothelial cancer.",
author = "Takuya Tsujino and Kiyoshi Takahara and Tomohisa Matsunaga and Yuki Yoshikawa and Tomoaki Takai and Taizo Uchimoto and Kenkichi Saito and Naoki Tanda and Hajime Hirano and Hayahito Nomi and Naokazu Ibuki and Teruo Inamoto and Haruhito Azuma",
year = "2017",
month = "4",
day = "10",
doi = "10.1186/s13256-017-1263-x",
language = "English",
volume = "11",
journal = "Journal of Medical Case Reports",
issn = "1752-1947",
publisher = "BioMed Central",
number = "1",

}

Tsujino, T, Takahara, K, Matsunaga, T, Yoshikawa, Y, Takai, T, Uchimoto, T, Saito, K, Tanda, N, Hirano, H, Nomi, H, Ibuki, N, Inamoto, T & Azuma, H 2017, 'Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report', Journal of Medical Case Reports, vol. 11, no. 1, 99. https://doi.org/10.1186/s13256-017-1263-x

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis : a case report. / Tsujino, Takuya; Takahara, Kiyoshi; Matsunaga, Tomohisa; Yoshikawa, Yuki; Takai, Tomoaki; Uchimoto, Taizo; Saito, Kenkichi; Tanda, Naoki; Hirano, Hajime; Nomi, Hayahito; Ibuki, Naokazu; Inamoto, Teruo; Azuma, Haruhito.

In: Journal of Medical Case Reports, Vol. 11, No. 1, 99, 10.04.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis

T2 - a case report

AU - Tsujino, Takuya

AU - Takahara, Kiyoshi

AU - Matsunaga, Tomohisa

AU - Yoshikawa, Yuki

AU - Takai, Tomoaki

AU - Uchimoto, Taizo

AU - Saito, Kenkichi

AU - Tanda, Naoki

AU - Hirano, Hajime

AU - Nomi, Hayahito

AU - Ibuki, Naokazu

AU - Inamoto, Teruo

AU - Azuma, Haruhito

PY - 2017/4/10

Y1 - 2017/4/10

N2 - Background: No standard chemotherapy regimen for advanced urothelial cancer has been established, except for cisplatin-based regimens. We report the case of a patient with double primary cancer, urothelial carcinoma of the upper urinary tract and colorectal cancer, who underwent oxaliplatin-based chemotherapies. Case presentation: A 56-year-old Japanese man presented to our hospital with the diagnosis of a left renal pelvic tumor and rectal cancer. Several examinations including ureteroscopic biopsy and computed tomography-guided biopsy were performed; however, the diagnosis of renal pelvic cancer could not be made. Because the rectal cancer had been growing during the course of examination, he underwent five cycles of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan. The volumes of both the rectal cancer and renal pelvic tumor drastically decreased. He then underwent pelvic evisceration with colostomy and ureterocutaneostomy. The histological diagnosis of the renal pelvic tumor was urothelial carcinoma. He is free of disease at 12 months after the treatment. Conclusions: To the best of our knowledge, this is the first report describing a remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy for renal pelvic cancer. We suggest fluorouracil, leucovorin, oxaliplatin, and irinotecan is an effective therapy for patients with advanced urothelial cancer.

AB - Background: No standard chemotherapy regimen for advanced urothelial cancer has been established, except for cisplatin-based regimens. We report the case of a patient with double primary cancer, urothelial carcinoma of the upper urinary tract and colorectal cancer, who underwent oxaliplatin-based chemotherapies. Case presentation: A 56-year-old Japanese man presented to our hospital with the diagnosis of a left renal pelvic tumor and rectal cancer. Several examinations including ureteroscopic biopsy and computed tomography-guided biopsy were performed; however, the diagnosis of renal pelvic cancer could not be made. Because the rectal cancer had been growing during the course of examination, he underwent five cycles of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan. The volumes of both the rectal cancer and renal pelvic tumor drastically decreased. He then underwent pelvic evisceration with colostomy and ureterocutaneostomy. The histological diagnosis of the renal pelvic tumor was urothelial carcinoma. He is free of disease at 12 months after the treatment. Conclusions: To the best of our knowledge, this is the first report describing a remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy for renal pelvic cancer. We suggest fluorouracil, leucovorin, oxaliplatin, and irinotecan is an effective therapy for patients with advanced urothelial cancer.

UR - http://www.scopus.com/inward/record.url?scp=85018467103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018467103&partnerID=8YFLogxK

U2 - 10.1186/s13256-017-1263-x

DO - 10.1186/s13256-017-1263-x

M3 - Article

VL - 11

JO - Journal of Medical Case Reports

JF - Journal of Medical Case Reports

SN - 1752-1947

IS - 1

M1 - 99

ER -